pmc logo image
Logo of bmjBMJ helping doctors make better decisionsSearchLatest content

Formats:

BMJ. 1992 April 11; 304(6832): 951–958.
PMCID: PMC1882326
Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.
M. M. Hawkins, L. M. Wilson, M. A. Stovall, H. B. Marsden, M. H. Potok, J. E. Kingston, and J. M. Chessells
Childhood Cancer Research Group, University of Oxford.
Abstract
OBJECTIVE--To investigate the incidence and aetiology of secondary leukaemia after childhood cancer in Britain. DESIGN--Cohort study and a case-control study. SETTING--Britain and population based National Register of Childhood Tumours. SUBJECTS--Cohort of 16,422 one year survivors of childhood cancer diagnosed in Britain between 1962 and 1983, among whom 22 secondary leukaemias were observed. A case-control study of 26 secondary leukaemias observed among survivors of childhood cancer diagnosed in Britain between 1940 and 1983; 96 controls were selected matched for sex, type of first cancer, age at first cancer, and interval to diagnosis of secondary leukaemia. MAIN OUTCOME MEASURES--Dose of radiation averaged over patients' active bone marrow and total accumulated dose of epipodophyllotoxins, alkylating agents, vinca alkaloids, antimetabolites, and antibiotics (mg/m2) given for the original cancer. RESULTS--Cumulative risk of secondary leukaemia within the cohort did not exceed 0.5% over the initial five years beyond one year survival, except that after non-Hodgkin's lymphomas 1.4% of patients developed secondary leukaemia. Corresponding figure for patients treated for non-Hodgkin's lymphomas in the early 1980s was 4%. The relative risk of secondary leukaemia increased significantly with exposure to epipodophyllotoxins and dose of radiation averaged over patients' active bone marrow. Ten patients developed leukaemia after having an epipodophyllotoxin-teniposide in nine cases, etoposide in one. Chromosomal translocations involving 11q23 were observed relating to two secondary leukaemias from a total of six for which there were successful cytogenetic studies after administration of an epipodophyllotoxin. CONCLUSIONS--Epipodophyllotoxins acting alone or together with alkylating agents or radiation seem to be involved in secondary leukaemia after childhood cancer.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Curtis RE, Hankey BF, Myers MH, Young JL., Jr Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience. J Natl Cancer Inst. 1984 Mar;72(3):531–544. [PubMed]
  • Kaldor JM, Day NE, Band P, Choi NW, Clarke EA, Coleman MP, Hakama M, Koch M, Langmark F, Neal FE, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer. 1987 May 15;39(5):571–585. [PubMed]
  • Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. [PubMed]
  • Devereux S, Selassie TG, Vaughan Hudson G, Vaughan Hudson B, Linch DC. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ. 1990 Nov 10;301(6760):1077–1080. [PubMed]
  • Boivin JF, Hutchison GB, Evans FB, Abou-Daoud KT, Junod B. Leukemia after radiotherapy for first primary cancers of various anatomic sites. Am J Epidemiol. 1986 Jun;123(6):993–1003. [PubMed]
  • Travis LB, Curtis RE, Boice JD, Jr, Hankey BF, Fraumeni JF., Jr Second cancers following non-Hodgkin's lymphoma. Cancer. 1991 Apr 1;67(7):2002–2009. [PubMed]
  • Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer. 1987 Sep;56(3):339–347. [PubMed]
  • Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990 Jan 4;322(1):7–13. [PubMed]
  • Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Høst H, Prior P, Karjalainen S, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 1990 Jan 4;322(1):1–6. [PubMed]
  • Haas JF, Kittelmann B, Mehnert WH, Staneczek W, Möhner M, Kaldor JM, Day NE. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987 Feb;55(2):213–218. [PubMed]
  • Tucker MA, Meadows AT, Boice JD, Jr, Stovall M, Oberlin O, Stone BJ, Birch J, Voûte PA, Hoover RN, Fraumeni JF., Jr Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst. 1987 Mar;78(3):459–464. [PubMed]
  • Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov;70(5):1412–1417. [PubMed]
  • Weh HJ, Kabisch H, Landbeck G, Hossfeld DK. Translocation (9;11)(p21;q23) in a child with acute monoblastic leukemia following 2 1/2 years after successful chemotherapy for neuroblastoma. J Clin Oncol. 1986 Oct;4(10):1518–1520. [PubMed]
  • Pui CH, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J, Jr, Kalwinsky DK, Dahl GV, Murphy SB. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989 Jul 20;321(3):136–142. [PubMed]
  • Pui CH, Hancock ML, Raimondi SC, Head DR, Thompson E, Wilimas J, Kun LE, Bowman LC, Crist WM, Pratt CB. Myeloid neoplasia in children treated for solid tumours. Lancet. 1990 Aug 18;336(8712):417–421. [PubMed]
  • Pui CH. Therapy-related myeloid leukaemia. Lancet. 1990 Nov 3;336(8723):1130–1131. [PubMed]
  • Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rørth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991 Aug 10;338(8763):359–363. [PubMed]
  • Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer. 1991 Aug 1;68(3):600–604. [PubMed]
  • Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. [PubMed]
  • Stovall M, Smith SA, Rosenstein M. Tissue doses from radiotherapy of cancer of the uterine cervix. Med Phys. 1989 Sep–Oct;16(5):726–733. [PubMed]
  • Secker-Walker LM, Stewart EL, Todd A. Acute lymphoblastic leukaemia with t(4;11) follows neuroblastoma: a late effect of treatment? Med Pediatr Oncol. 1985;13(1):48–50. [PubMed]
  • Darbyshire PJ, Mott MG. Secondary acute myeloid leukaemia in a boy with T-cell lymphoma: successful treatment by bone marrow transplantation. Clin Lab Haematol. 1986;8(1):71–75. [PubMed]
  • DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann Intern Med. 1989 May 1;110(9):740–742. [PubMed]
  • Prieto F, Palau F, Badia L, Beneyto M, Perez-Sirvent ML, Orts A, Castel V. 11q23 abnormalities in children with acute nonlymphocytic leukemia (M4-M5). Association with previous chemotherapy. Cancer Genet Cytogenet. 1990 Mar;45(1):1–11. [PubMed]
  • Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar;4(3):325–345. [PubMed]
  • Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986 Dec;4(12):1748–1757. [PubMed]
  • Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita VT., Jr Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood. 1988 Feb;71(2):403–414. [PubMed]
  • Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group. Cancer Genet Cytogenet. 1988 May;32(1):1–10. [PubMed]
  • Boice JD, Jr, Greene MH, Killen JY, Jr, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni JF., Jr Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983 Nov 3;309(18):1079–1084. [PubMed]
  • Greene MH, Harris EL, Gershenson DM, Malkasian GD, Jr, Melton LJ, 3rd, Dembo AJ, Bennett JM, Moloney WC, Boice JD., Jr Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986 Sep;105(3):360–367. [PubMed]
  • Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer. 1987 May;55(5):523–529. [PubMed]
  • de Vathaire F, François P, Hill C, Schweisguth O, Rodary C, Sarrazin D, Oberlin O, Beurtheret C, Dutreix A, Flamant R. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer. 1989 May;59(5):792–796. [PubMed]
  • Ingram L, Mott MG, Mann JR, Raafat F, Darbyshire PJ, Morris Jones PH. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer. 1987 Apr;55(4):463–466. [PubMed]
  • Mott MG, Eden OB, Palmer MK. Adjuvant low dose radiation in childhood non-Hodgkin's lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG). Br J Cancer. 1984 Oct;50(4):463–469. [PubMed]
  • Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res. 1985 Jul;45(7):3106–3112. [PubMed]
  • Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec;44(12 Pt 1):5857–5860. [PubMed]
  • Boice JD, Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst. 1987 Dec;79(6):1295–1311. [PubMed]
  • Mott MG, Chessells JM, Willoughby ML, Mann JR, Morris-Jones PH, Malpas JS, Palmer MK. Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG). Br J Cancer. 1984 Oct;50(4):457–462. [PubMed]
  • Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991 Dec 12;325(24):1682–1687. [PubMed]